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Abstract
In recent years, many potential antifibrotic treatment strategies have emerged from molecular studies
of systemic sclerosis. Few biologicals have already entered clinical trials and these may hopefully
prove to be effective in this progressive, profibrotic disease.
Introduction and context
Vasculopathy, autoimmunity, and fibrosis are hallmarks
of systemic sclerosis (SSc), a profibrotic disease that
affects the skin and multiple internal organs, including
the lungs, kidneys, gut, and heart [1]. In the late stages of
SSc, progressive tissue fibrosis and organ failure cause
high morbidity and increased mortality. Therapeutic
options to treat patients with SSc symptomatically are
limited, and causal therapies do not exist. In recent years,
however, researchers have identified several key profi-
brotic molecules in the pathogenesis of SSc and have
developed antifibrotic therapies, which now can be
evaluated in clinical studies. Findings in preclinical
models of SSc raised hopes that these antifibrotic
therapeutics might restrain tissue fibrosis and alleviate
patients’ symptoms. Because of their mode of action,
however, the antifibrotic therapies cannot target vasculo-
pathy and autoimmune disease in patients with SSc. To
develop causal treatment strategies, we still need to learn
more about the pathogenesis of SSc.
Recent advances
Both in vitro and in vivo studies indicate the central role of
transforming growth factor-beta (TGF-b) in the develop-
ment of fibrosis in SSc. TGF-b stimulates fibroblasts
to produce excessive amounts of extracellular matrix
proteins, the predominant components of fibrotic tissue.
Thus, inhibition of TGF-b signaling can reduce tissue
fibrosis in experimental models of SSc [2]. Nevertheless,
recombinant TGF-b1-neutralizing antibodies (CAT-192)
failed to show efficacy in the first multi-center rando-
mized placebo-controlled phase I/II trial [3]. Insufficient
affinity to TGF-b1 in vivo might explain treatment failure
with the CAT-192 antibodies (Figure 1).
Imatinib interferes with two important profibrotic path-
ways in SSc as it inhibits the TGF-b downstream kinase
c-Abl and the tyrosine kinase activity of platelet-derived
growth factor (PDGF) receptors [4]. In a murine model of
radiation-induced pulmonary injury, imatinib inhibited
the development of lung fibrosis [5]. In several experi-
mental models of SSc, we demonstrated that imatinib
prevented the development of fibrosis and reduced
established skin fibrosis, suggesting its efficacy in both
early and late stages of the disease [6,7]. Of note, smaller
clinical studies in patients with chronic myelogenous
leukemia (CML), in which imatinib is a first-line therapy,
demonstrated regression of bone marrow fibrosis [8,9]. In
addition, the first case reports indicated that imatinib
mesylate could reduce established fibrosis inpatientswith
SSc, mixed connective tissue disease, and nephrogenic
fibrosis [10-12]. As shown by two recent studies, imatinib
is highly effective in patients with refractory chronic graft-
versus-host disease, which shares several pathologic
features with SSc, including progressive skin fibrosis
[13,14]. The antifibrotic effects in experimental models
of SSc, its efficacy in other profibrotic disorders, and the
large clinical experience from the treatment of CML
prompted clinical trials currently evaluating the efficacy of
imatinib in patients with SSc.
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and the PDGF receptor, serve as salvage therapies for the
treatment of refractory CML and in patients with
intolerance to imatinib [15]. Similar to imatinib,
dasatinib and nilotinib inhibited the development of
fibrosis in in vitro and in vivo models of SSc and therefore
might be interesting alternatives in the antifibrotic
treatment with tyrosine kinase inhibitors. In addition
to its direct effects on c-Abl and the PDGF receptor,
dasatinib inhibits Src kinases. These enzymes regulate
the activation of c-Abl and are activated by profibrotic
cytokines, such as TGF-b and PDGF. In experimental
models of SSc, the specific inhibitor of Src kinase,
SU6656, reduced the development of dermal fibrosis.
Thus, targeting of Src kinases may be another promising
approach in the treatment of SSc [16].
Peroxisome proliferator-activated receptor-gamma
(PPAR-g) is a member of the nuclear hormone receptor
superfamily, which can activate a number of biological
effects, including alterations in metabolic and inflam-
matory responses. The thiazolidinediones, a group of
clinically approved PPAR-g agonists, lower blood glu-
cose levels in patients with type 2 diabetes. PPAR-g
agonists also suppressed cell activation and collagen
production in skin and lung fibroblasts and inhibited the
development of fibrosis in murine models [17-19].
As targeted therapies in patients with malignancies,
histone deacetylase (HDAC) inhibitors induce cell cycle
arrest, cell differentiation, and apoptotic cell death of
tumor cells [20]. Besides the cytotoxic effects on tumor
cells, HDAC inhibitors can reduce the development of
TGF-b- and PDGF-induced fibrosis in experimental
models of SSc. The non-selective inhibitor trichostatin A
(TSA) inhibited TGF-b signaling by preventing the nuclear
translocation and the DNA binding of Smad3/Smad4
complexes in dermal fibroblasts. Upregulation of the cell
cycle inhibitor p21 upon treatment with TSA may also
reduce activation of fibroblasts and excessive production
of extracellular matrix components [21]. Since the first
clinical trials in patients with malignancies reported low
toxicity, the antifibrotic effects in the preclinical models
encourage clinical trials with TSA in SSc patients. Selective
HDAC inhibitors (e.g., against HDAC-7) might offer even
higher efficacy and lower toxicity [22].
Similar to HDACs, DNA methyltransferases (DNMTs)
regulate DNA transcription by modifying the accessi-
bility of genes to the transcription machinery. In vitro
experiments demonstrated that the DNMT inhibitor
5-Aza-2-deoxycytidine decreased the release of collagen
by restoring the transcription of Fli-1, which is hyper-
methylated and thereby silenced in SSc fibroblasts [23].
Furthermore, we showed that 5-Aza-2-deoxycytidine and
other inhibitors of DNMTs, including procainamide and
hydralazine, prevented the development of fibrosis in
in vivo models of SSc [24].
Implications for clinical practice
The thorough work of many researchers in our field has
led to a better understanding of profibrotic pathways, the
identification of target molecules, and the development
of new therapeutic strategies in SSc. The tyrosine kinase
inhibitor imatinib is currently under clinical evaluation
for the treatment of patients with SSc and we are awaiting
critical data from these trials. In contrast, the failure of
the TGF-b1-neutralizing CAT-192 antibodies in vivo
requires further investigation. Since the pathogenesis of
SSc remains enigmatic, we still face a lot of work to
develop causal therapies for the treatment of SSc.
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Figure 1. Novel antifibrotic therapies in systemic sclerosis (SSc)
Excessive accumulation of extracellular matrix (ECM) causes severe tissue
fibrosis in SSc. Antifibrotic therapies target profibrotic pathways in fibroblasts,
the main producers of ECM.
1CAT-192 anti-transforming growth factor-b
antibodies (TGF-ab) catch TGF-b molecules (TGF), which would bind to
TGF-b receptors (TGFR) to activate potent profibrotic pathways. Smad
molecules, including Smad 3, as well as the Abelson kinase (Abl) are
downstream mediators of the profibrotic TGF-b pathway.
2Receptor tyrosine
kinase inhibitors (RTKI) can block several profibrotic signaling cascades.
Imatinib and nilotinib inhibit both Abl and the platelet-derived growth factor
receptor (PDGFR). In addition to Abl and PDGFR, dasatinib blocks Src
kinases (Src).
3The thiazolidinediones, a group of peroxisome proliferator-
activated receptor-gamma agonists (PPARgA), bind to their intra-nuclear
receptors to inhibit ECM production.
4Histone deacetylase inhibitors
(HDACI) as well as
5DNA methyltransferase inhibitors (DNMTI) decrease
ECM production by modifying gene transcription.
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